Hainan Yuekang’s YK-029A Biosimilar Set for BTD in EGFR ex20ins NSCLC
The Center for Drug Evaluation (CDE) website indicates that China-based Hainan Yuekang Biological Medicine Co.,...
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO
China-based Innovent Biologics, Inc. (HKG: 1801) presented results of the ORIENT-31 study for its PD-1...
Luye Pharma’s CD25 Monoclonal Antibody BA1106 Gains NMPA Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Fosun Pharma Inks Licensing Deal with Neovii for GvHD Therapy Grafalon
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) signed an exclusive licensing...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
HutchMed’s Elunate Shows Survival Benefit in Global CRC Study at ESMO
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the results of the pivotal...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical...
Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem
Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo...
Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19...
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...
CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development
CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has...
Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...
SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC
China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...
Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits
Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United...
Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...